Clinical Trial Update: A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial on QBW251 in COPD completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QBW251

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Status: COMPLETED | Results posted: 2018-04-02